Year: 2012
Type: article
Abstract: Invasive fungal infections are devastating. Despite state-of-the-art antifungal therapy, the mortality rates for invasive infections with the three most common species of human fungal pathogens are Candida albicans, 20%–40 % [1]; Aspergillus fumigatus, 50%–90% [1]; and Cryptococcus neoformans, 20%–70 % [2]. Although invasive fungal infections can affect people with intact immune systems, the vast majority of disease occurs in the setting of an immunocom-promised host. As discussed recently, the dismal outcomes for invasive fungal infections cannot be completely attributed to a lack of efficacious antifungal drugs [3]. However, because most patients with invasive fungal infections are immunocompromised, the immune system cannot effectively assist in the clearance of the infection, and consequently, the success of treatment is more dependent on the efficacy of the antifungal agent than in the setting of an immunocompetent host. Unfortunately, our reper-
Source: PLoS Pathogens
Authors: Arielle Butts, Damian J. Krysan
Institutions: University of Rochester, University of Rochester Medicine
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,043
OpenAlex ID: W2048074482
